Skip to main content
KTTA
NASDAQ Life Sciences

Pasithea Q3 Loss Widens to $6.6M as R&D Spend Triples; $41.2M Cash Remains

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.479
Mkt Cap
$17.442M
52W Low
$0.281
52W High
$2.06
52W Position info
70% above low
Off High info
77% below high
Rel. Volume info
3.6× avg
Market data snapshot near publication time

KTTA sits 70% above its 52-week low of $0.281 on elevated volume (3.6× avg).

Summary

Pasithea's Q3 2026 net loss widened to $6.58 million as R&D spending more than tripled, leaving $41.2 million in cash that management says funds at least 12 months of operations.


Key Events · Earnings and Guidance · KTTA

  • Q3 Loss Widens on R&D Ramp

    The net loss came to $6,579,393 for the three months ended September 30, 2026, versus $3,037,420 a year earlier; for the nine months, the loss was $14,722,727 versus $10,316,815.

  • R&D Spending More Than Triples

    Research and development rose 228.3% to $4,457,107 in Q3 2026, driven by $2,570,000 of higher clinical trial and regulatory costs; G&A rose 43.4% to $2,512,575.

  • Cash Falls but Runway Affirmed

    Cash and equivalents stood at $41,218,508 at September 30, 2026, down from $55,158,939 at December 31, 2025; management concluded there is no substantial doubt about going concern and that funding covers at least 12 months.

  • Share Count Climbs on Warrant Exercises

    Shares outstanding reached 33,414,448 at September 30, 2026 versus 23,091,062 at year-end 2025; 10,324,500 pre-funded warrants were exercised in the nine months and 3,338,100 more between October 1 and November 12, 2026, with 51,490,735 pre-funded warrants still outstanding.


Analysis · KTTA · Life Sciences

A sharply wider quarterly loss reflects Pasithea's ramp-up on PAS-004, the MEK inhibitor that just delivered its first efficacy data in NF1 patients. Research and development jumped 228.3% to $4.46 million in the quarter, driving a $6.58 million net loss versus $3.04 million a year earlier. The offsetting positive sits on the balance sheet: $41.2 million of cash and equivalents at September 30, down from $55.2 million at year-end 2025, with management stating it has no substantial doubt about going concern and enough funding for at least 12 months. That runway matters because the company is now funding a Phase 2 cNF trial cleared by the FDA in November 2026 alongside the ongoing Phase 1/1b PN study. Dilution is already embedded: 33.4 million shares outstanding at quarter-end versus 23.1 million at December 31, 2025, plus 51.5 million pre-funded warrants still exercisable at $0.001, and 3.34 million more exercised since quarter-end.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KTTA was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.4M. The 52-week trading range was $0.28 to $2.06. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KTTA - Latest Insights

KTTA
Nov 13, 2026, 2:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.510
Real-time Price: $0.485 info
Change: -$0.025 (-5%) info
Market Cap: $17.442M info
KTTA
Nov 03, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.3591
Real-time Price: $0.485 info
Change: +$0.1259 (+35%) info
Market Cap: $17.442M info
KTTA
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.550
Real-time Price: $0.485 info
Change: -$0.065 (-12%) info
Market Cap: $17.442M info
KTTA
Sep 09, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.5697
Real-time Price: $0.485 info
Change: -$0.0847 (-15%) info
Market Cap: $17.442M info
KTTA
Aug 21, 2026, 5:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.490
Real-time Price: $0.485 info
Change: -$0.0050 (-1%) info
Market Cap: $17.442M info